Sartorius Aktiengesellschaft (SRT) - Net Assets
Based on the latest financial reports, Sartorius Aktiengesellschaft (SRT) has net assets worth €3.79 Billion EUR (≈ $4.44 Billion USD) as of June 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€10.03 Billion ≈ $11.72 Billion USD) and total liabilities (€6.23 Billion ≈ $7.29 Billion USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check how resilient are Sartorius Aktiengesellschaft's assets to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €3.79 Billion |
| % of Total Assets | 37.84% |
| Annual Growth Rate | 21.68% |
| 5-Year Change | 177.98% |
| 10-Year Change | 504.54% |
| Growth Volatility | 14.62 |
Sartorius Aktiengesellschaft - Net Assets Trend (2013–2024)
This chart illustrates how Sartorius Aktiengesellschaft's net assets have evolved over time, based on quarterly financial data. Also explore SRT asset base for the complete picture of this company's asset base.
Annual Net Assets for Sartorius Aktiengesellschaft (2013–2024)
The table below shows the annual net assets of Sartorius Aktiengesellschaft from 2013 to 2024. For live valuation and market cap data, see SRT company net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | €3.90 Billion ≈ $4.56 Billion |
+41.33% |
| 2023-12-31 | €2.76 Billion ≈ $3.22 Billion |
+3.73% |
| 2022-12-31 | €2.66 Billion ≈ $3.11 Billion |
+54.57% |
| 2021-12-31 | €1.72 Billion ≈ $2.01 Billion |
+22.68% |
| 2020-12-31 | €1.40 Billion ≈ $1.64 Billion |
+29.69% |
| 2019-12-31 | €1.08 Billion ≈ $1.26 Billion |
+11.08% |
| 2018-12-31 | €973.39 Million ≈ $1.14 Billion |
+20.68% |
| 2017-12-31 | €806.56 Million ≈ $942.95 Million |
+9.47% |
| 2016-12-31 | €736.80 Million ≈ $861.40 Million |
+14.28% |
| 2015-12-31 | €644.75 Million ≈ $753.78 Million |
+29.56% |
| 2014-12-31 | €497.66 Million ≈ $581.82 Million |
+10.53% |
| 2013-12-31 | €450.25 Million ≈ $526.39 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Sartorius Aktiengesellschaft's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 100.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | €2.76 Billion | 100.00% |
| Total Equity | €2.76 Billion | 100.00% |
Sartorius Aktiengesellschaft Competitors by Market Cap
The table below lists competitors of Sartorius Aktiengesellschaft ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Northam Platinum Holdings Ltd
JSE:NPH
|
$6.70 Billion |
|
Sailun Jinyu Group Co Ltd
SHG:601058
|
$6.70 Billion |
|
Geovis Technology Co Ltd
SHG:688568
|
$6.70 Billion |
|
KINGFISHER ADR/2 LS-1571
F:KFI2
|
$6.70 Billion |
|
Yunnan Lincang Xinyuan Germanium Industrial Co Ltd
SHE:002428
|
$6.69 Billion |
|
Shenghe Resources Holding Co Ltd
SHG:600392
|
$6.68 Billion |
|
Nuvalent Inc
NASDAQ:NUVL
|
$6.66 Billion |
|
Noble Corporation plc
NYSE:NE
|
$6.66 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Sartorius Aktiengesellschaft's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 2,067,800,000 to 2,764,800,000, a change of 697,000,000 (33.7%).
- Net income of 84,000,000 contributed positively to equity growth.
- Dividend payments of 50,700,000 reduced retained earnings.
- New share issuances of 198,300,000 increased equity.
- Other factors increased equity by 465,400,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €84.00 Million | +3.04% |
| Dividends Paid | €50.70 Million | -1.83% |
| Share Issuances | €198.30 Million | +7.17% |
| Other Changes | €465.40 Million | +16.83% |
| Total Change | €- | 33.71% |
Book Value vs Market Value Analysis
This analysis compares Sartorius Aktiengesellschaft's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 4.18x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 18.51x to 4.18x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | €9.03 | €167.20 | x |
| 2018-12-31 | €10.83 | €167.20 | x |
| 2019-12-31 | €11.85 | €167.20 | x |
| 2020-12-31 | €15.31 | €167.20 | x |
| 2021-12-31 | €18.42 | €167.20 | x |
| 2022-12-31 | €29.08 | €167.20 | x |
| 2023-12-31 | €30.22 | €167.20 | x |
| 2024-12-31 | €40.05 | €167.20 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Sartorius Aktiengesellschaft utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 3.04%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 2.48%
- • Asset Turnover: 0.33x
- • Equity Multiplier: 3.65x
- Recent ROE (3.04%) is below the historical average (18.30%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2013 | 14.26% | 6.62% | 0.67x | 3.21x | €15.66 Million |
| 2014 | 12.19% | 5.44% | 0.70x | 3.20x | €8.70 Million |
| 2015 | 24.40% | 11.33% | 0.78x | 2.78x | €74.53 Million |
| 2016 | 17.76% | 7.92% | 0.74x | 3.02x | €44.97 Million |
| 2017 | 18.57% | 8.17% | 0.61x | 3.72x | €52.95 Million |
| 2018 | 19.09% | 9.03% | 0.62x | 3.41x | €67.29 Million |
| 2019 | 19.34% | 8.58% | 0.64x | 3.51x | €75.71 Million |
| 2020 | 21.60% | 9.69% | 0.50x | 4.48x | €121.51 Million |
| 2021 | 25.30% | 9.25% | 0.61x | 4.52x | €192.86 Million |
| 2022 | 34.08% | 16.24% | 0.60x | 3.51x | €479.12 Million |
| 2023 | 9.94% | 6.05% | 0.35x | 4.71x | €-1.18 Million |
| 2024 | 3.04% | 2.48% | 0.33x | 3.65x | €-192.48 Million |
Industry Comparison
This section compares Sartorius Aktiengesellschaft's net assets metrics with peer companies in the Medical Instruments & Supplies industry.
Industry Context
- Industry: Medical Instruments & Supplies
- Average net assets among peers: $5,621,340,699
- Average return on equity (ROE) among peers: -86.39%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Sartorius Aktiengesellschaft (SRT) | €3.79 Billion | 14.26% | 1.64x | $6.69 Billion |
| SCHOTT Pharma AG & Co. KGaA (1SXP) | $709.04 Million | 17.68% | 0.69x | $2.39 Billion |
| RENAU.UNSP.ARD 1/5 EO-20 (56S0) | $2.51 Billion | 34.85% | 1.01x | $16.46 Billion |
| MEDIMI AB AK (79T) | $332.69K | -959.52% | 4.12x | $427.04K |
| TEVANO SYSTEMS HLDGS INC. (7RBA) | $-1.31 Million | 0.00% | 0.00x | $210.67K |
| STEVANATO GROUP SPA O.N. (87N) | $841.66 Million | 15.96% | 0.69x | $831.06 Million |
| Carl Zeiss Meditec AG (AFX) | $797.45 Million | 7.81% | 0.43x | $2.23 Billion |
| CARL ZEISS MEDITEC ADR 1 (AFXA) | $2.06 Billion | 8.69% | 0.65x | $2.14 Billion |
| Bio-gate AG (BIG1) | $1.55 Million | -51.89% | 1.13x | $5.32 Million |
| COLOPLAST SP.ADR 1/10 DK1 (CBH) | $8.29 Billion | 56.75% | 3.52x | $12.73 Billion |
| ESSILORLUXOTTICA 1/2/O.N. (ESLC) | $41.00 Billion | 5.75% | 0.57x | $93.24 Billion |
About Sartorius Aktiengesellschaft
Sartorius Aktiengesellschaft provides bioprocess solutions, and lab products and services worldwide. The company offers multi-parallel, benchtop, single-use, stainless steel, cell culture, rocking motion, and microbial bioreactors; software apps for bioreactors and cell culture shake flasks; fermenters; cell culture media, biolayer interferometry, microbiological testing, and fluid management pro… Read more